Which quality requirements apply to ATMPs in Germany?
Welcome to the second post in the quality assurance series, focusing on the hot topic of ATMPs! Next week, I’ll be focusing
Tag: CAR-T
The G-BA specifies QA requirements for cell and gene therapies in Germany
In the previous assessments of Kymriah, Yescarta, Tecartus, and Zolgensma, the G-BA had defined specific QA requirements for the use of these
G-BA assessment of CAR-T therapy Tecartus
The G-BA has now completed its benefit assessment of the CAR-T therapy, Tecartus, which is indicated for the treatment of mantle cell